Egg Oral Immunotherapy
NCT01489553 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9
Last updated 2013-10-22
Summary
For patients with Immunoglobulin E (IgE)-mediated food allergy, the current management includes identification of the causative food and avoidance. Egg allergy is among the most common causes of IgE-mediated food allergy in children, affecting approximately 1.6% of children (its prevalence is higher in children with atopic dermatitis or other food allergies). Given the prevalence of egg and the difficulty to avoid it in the diet, we aim to investigate the safety and efficacy of baked egg oral immunotherapy.
Conditions
- Egg Hypersensitivity
Sponsors & Collaborators
-
Children's Hospital of Philadelphia
lead OTHER
Principal Investigators
-
Jonathan M. Spergel, MD, PhD · Children's Hospital of Philadelphia
-
Rushani W. Saltzman, MD · Children's Hospital of Philadelphia
Eligibility
- Min Age
- 6 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-01-31
- Primary Completion
- 2013-09-30
- Completion
- 2013-10-31
More Related Trials
-
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
NCT05247866 ·Status: COMPLETED ·Phase: PHASE4
-
Dupilumab Therapy for EGIDs
NCT07257835 ·Status: RECRUITING
-
Effect of Anti-IgE in Chronic Urticaria
NCT00130234 ·Status: COMPLETED ·Phase: PHASE2
-
Omalizumab in the Treatment of Peanut Allergy
NCT00949078 ·Status: COMPLETED ·Phase: PHASE2
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
NCT01781637 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Oral Immunotherapy (OIT) for Peanut Allergy
NCT00815035 ·Status: COMPLETED ·Phase: PHASE2
-
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
NCT01510626 ·Status: COMPLETED ·Phase: PHASE1
-
Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model
NCT01040598 ·Status: COMPLETED ·Phase: PHASE1
-
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
NCT03881696 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (EgE)-Mediated Food Allergy Previously Treated With Linvoseltamab
NCT06631677 ·Status: TEMPORARILY_NOT_AVAILABLE
-
E-B-FAHF-2, Multi OIT and Xolair for Food Allergy
NCT06103656 ·Status: COMPLETED ·Phase: PHASE2
-
E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy
NCT02879006 ·Status: UNKNOWN ·Phase: PHASE2
-
Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)
NCT04037176 ·Status: COMPLETED ·Phase: PHASE4
-
Mepolizumab in Episodic Angioedema With Eosinophilia
NCT04128371 ·Status: TERMINATED ·Phase: PHASE2
-
EoE Food Test Pilot Study
NCT07023380 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Xolair Treatment for Milk Allergic Children
NCT00968110 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
NCT00123630 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
NCT00358449 ·Status: COMPLETED ·Phase: PHASE2
-
Omalizumab to Treat Hyper-IgE (Job's) Syndrome
NCT00260702 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
NCT04056299 ·Status: TERMINATED ·Phase: PHASE2
-
Peanut Oral Immunotherapy in Children
NCT01867671 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
NCT02402231 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
NCT06618963 ·Status: RECRUITING ·Phase: PHASE4
-
Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy
NCT04148352 ·Status: TERMINATED ·Phase: PHASE2
-
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
NCT00635089 ·Status: COMPLETED ·Phase: PHASE3